Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Fenofibrate attenuates impaired ischemic preconditioning-mediated cardioprotection in the fructose-fed hypertriglyceridemic rat heart.
Babbar L, Mahadevan N, Balakumar P.
Naunyn Schmiedebergs Arch Pharmacol. 2013 Apr;386(4):319-29. doi: 10.1007/s00210-012-0830-3. Epub 2013 Jan 17.
Related citations
Biomedical research - from ideation to publication.
Balakumar P.
J Nat Sci Biol Med. 2012 Jul;3(2):212. doi: 10.4103/0976-9668.101938. No abstract available.
Fish Oil Blunted Nicotine-Induced Vascular Endothelial Abnormalities Possibly via Activation of PPARγ-eNOS-NO Signals.
Taneja G, Mahadevan N, Balakumar P.
Cardiovasc Toxicol. 2013 Jun;13(2):110-22. doi: 10.1007/s12012-012-9190-y.
Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities.
Kathuria S, Mahadevan N, Balakumar P.
Mol Cell Biochem. 2013 Feb;374(1-2):61-72. doi: 10.1007/s11010-012-1505-6. Epub 2012 Nov 10.
Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy.
Kadian S, Mahadevan N, Balakumar P.
Eur J Pharmacol. 2013 Jan 5;698(1-3):388-96. doi: 10.1016/j.ejphar.2012.10.012. Epub 2012 Oct 18.
Adenosine transport blockade restores attenuated cardioprotective effects of adenosine preconditioning in the isolated diabetic rat heart: potential crosstalk with opioid receptors.
Sharma NK, Mahadevan N, Balakumar P.
Cardiovasc Toxicol. 2013 Mar;13(1):22-32. doi: 10.1007/s12012-012-9182-y.
The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat.
Bishnoi HK, Mahadevan N, Balakumar P.
Pharmacol Res. 2012 Oct;66(4):349-56. doi: 10.1016/j.phrs.2012.07.001. Epub 2012 Jul 14.
The basic concepts of scientific research and scientific communication.
Balakumar P, Jagadeesh G.
J Pharmacol Pharmacother. 2012 Apr;3(2):178-82. doi: 10.4103/0976-500X.95522. No abstract available.
Fish oil and vascular endothelial protection: bench to bedside.
Balakumar P, Taneja G.
Free Radic Biol Med. 2012 Jul 15;53(2):271-9. doi: 10.1016/j.freeradbiomed.2012.05.005. Epub 2012 May 12. Review.
How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?
Jagadeesh G, Balakumar P, Stockbridge N.
Cell Signal. 2012 Aug;24(8):1583-91. doi: 10.1016/j.cellsig.2012.04.003. Epub 2012 Apr 13. Review.
Telmisartan in the management of diabetic nephropathy: a contemporary view.
Balakumar P, Bishnoi HK, Mahadevan N.
Curr Diabetes Rev. 2012 May;8(3):183-90. Review.
Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders.
Balakumar P, Kathuria S.
Br J Pharmacol. 2012 Aug;166(7):1981-92. doi: 10.1111/j.1476-5381.2012.01938.x. Review.
Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?
Balakumar P, Kadian S, Mahadevan N.
Pharmacol Res. 2012 Apr;65(4):430-6. doi: 10.1016/j.phrs.2012.01.004. Epub 2012 Jan 21. Review.
PPAR ligands and cardiovascular disorders: friend or foe.
Curr Mol Pharmacol. 2012 Jun;5(2):219-23. No abstract available.
Preconditioning the hyperlipidemic myocardium: fact or fantasy?
Balakumar P, Babbar L.
Cell Signal. 2012 Mar;24(3):589-95. doi: 10.1016/j.cellsig.2011.11.003. Epub 2011 Nov 9. Review.
Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
Balakumar P, Kathuria S, Taneja G, Kalra S, Mahadevan N.
J Mol Cell Cardiol. 2012 Jan;52(1):83-92. doi: 10.1016/j.yjmcc.2011.09.014. Epub 2011 Sep 24. Review.
Healing the diabetic heart: does myocardial preconditioning work?
Balakumar P, Sharma NK.
Cell Signal. 2012 Jan;24(1):53-9. doi: 10.1016/j.cellsig.2011.09.007. Epub 2011 Sep 16. Review.
Potential cross-talk between (pro)renin receptors and Wnt/frizzled receptors in cardiovascular and renal disorders.
Hypertens Res. 2011 Nov;34(11):1161-70. doi: 10.1038/hr.2011.113. Epub 2011 Jul 28. Review.
Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?
Balakumar P, Mahadevan N.
Br J Pharmacol. 2012 Jan;165(2):373-9. doi: 10.1111/j.1476-5381.2011.01597.x. Review.
Cardiovascular and renal pathologic implications of prorenin, renin, and the (pro)renin receptor: promising young players from the old renin-angiotensin-aldosterone system.
J Cardiovasc Pharmacol. 2010 Nov;56(5):570-9. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on